The FDA has approved a new breast tomosynthesis solution from GE Healthcare (Chalfont, UK) that is designed with a 3-D imaging technology. GE developed SenoClaire in collaboration with Massachusetts General Hospital (Mass General; Boston). The technology uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a step-and-shoot method, removing the potential motion from the tube, helping to reduce blur and increase image sharpness, the company said.